NCT03275311 Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 Status RECRUITING Phase N/A
NCT03272334 Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03266744 Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study Status UNKNOWN Phase NA
NCT03262935 SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer Status COMPLETED Phase PHASE3
NCT03251378 A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers Status COMPLETED Phase PHASE1
NCT03243331 An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer Status COMPLETED Phase PHASE1
NCT03241810 Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer Status TERMINATED Phase PHASE2
NCT03238196 Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer Status COMPLETED Phase PHASE1
NCT03227328 CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO Status COMPLETED Phase PHASE2
NCT03195192 Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer Status COMPLETED Phase NA
NCT03184090 Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC Status COMPLETED Phase PHASE2
NCT03166085 PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer Status COMPLETED Phase PHASE1
NCT03161834 Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer Status WITHDRAWN Phase N/A
NCT03151447 Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer Status UNKNOWN Phase PHASE1
NCT03147287 Palbociclib After CDK and Endocrine Therapy (PACE) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03143322 Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases Status ACTIVE_NOT_RECRUITING Phase NA
NCT03139851 Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide Status COMPLETED Phase PHASE2